Form 4: Beta Bionics Director Sean Carney Acquires Stock Options
SEC Form 4 Filing
Director Sean Carney of Beta Bionics, Inc. acquired stock options on January 31, 2025, for 86,293 shares of common stock.
Summary
- Sean Carney, a director at Beta Bionics, Inc., was granted stock options on January 31, 2025.
- These options allow him to purchase a total of 86,293 shares of common stock.
- The options are divided into two grants: one for 55,837 shares and another for 30,456 shares.
- The exercise price for both options is $7.51 per share.
- The first option vests in 36 equal monthly installments from February 12, 2020, and expires on May 14, 2030.
- The second option vests in 36 equal monthly installments from July 27, 2022, and expires on July 26, 2032.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.
Positives
- The granting of stock options to a director aligns their interests with the company's success.
- The vesting schedules encourage long-term commitment from the director.
Industry Context
This is a standard practice for incentivizing directors in publicly traded companies, particularly in the biotech sector where long-term growth is a key focus.
Comparison to Industry Standards
- Stock option grants are a common form of compensation for directors in publicly traded companies, especially in the biotech industry.
- The vesting schedules of 36 months are typical for such grants, aligning with industry standards for long-term incentives.
- The exercise price of $7.51 is specific to Beta Bionics and would need to be compared to the current market price of the stock to assess its value.
Stakeholder Impact
- The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
- The grant does not have any immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/12/2020 | Start date for vesting of the first stock option grant. |
| 07/27/2022 | Start date for vesting of the second stock option grant. |
| 01/31/2025 | Date of the stock option grant. |
| 02/03/2025 | Date the form was signed. |
| 05/14/2030 | Expiration date of the first stock option grant. |
| 07/26/2032 | Expiration date of the second stock option grant. |
Keywords
stock options, insider trading, director, equity, Beta Bionics, BBNX, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.